ANZCTR search results

The Health4Life Parents & Teens study aims to test a new digital intervention to improve six key health risk behaviours in adolescents: physical inactivity, poor nutrition, alcohol use, smoking/vaping, screen time, and poor sleep. This study will test the effects of the combined student-and-parent program in improving teenage health habits, especially those facing disadvantage. The Health4Life student program, which will be delivered to Year 7 students during PHDPE class, uses interactive cartoons to encourage young people to adopt the six key health behaviours. This program has been adapted to specifically help young people experiencing socioeconomic disadvantage. The Health4Life parent program compliments this, providing parents with online modules and tailored feedback about their parenting practices in relation to the six key health behaviours. Findings will provide evidence about the efficacy of this digital program in reducing key health risk behaviours among teenagers experiencing disadvantage, and much-needed cost-effectiveness data.

The purpose of the study is to identify if brain waves recorded during anaesthesia and surgery can be used to predict if patients will develop delirium after surgery. We will collect brain wave activity from patients using a special cap (similar to a shower cap). We will also collect blood from patients to measure proteins that might also indicate their risk of developing delirium. The aim is to predict patients who might develop delirium in order to help prevent this complication of anaesthesia and surgery.

People with type 2 diabetes or pre-diabetes respond differently to medications. This study aims to understand why, and whether certain features of metabolism can help predict which diabetes medicines may work best for different people. In this study we will assess how blood glucose and insulin levels change during treatment with three commonly used diabetes medicines: metformin, tirzepatide and empagliflozin.

This study is a prospective randomised controlled trial (RCT) investigating post-operative clinical outcomes in paediatric patients undergoing medial patellofemoral ligament (MPFL) reconstruction for recurrent patellofemoral instability using either a quadriceps tendon (QT) graft or a hamstring tendon (HT) graft. Outcomes will be collected from baseline (pre-operative) through to 24 months post-operatively and will include patient-reported outcomes, objective functional measures (clinical examination, strength and performance testing) and radiological measures.

This study aims to understand how the brain and nervous system control muscle strength, particularly when a limb is not being used. When a limb is immobilised (for example, in a cast or brace), muscle strength can decline quickly, and this may be due more to changes in the brain than the muscle itself. In this study, healthy adults will wear a wrist brace to temporarily restrict movement of one arm for up to two weeks. Some participants will also perform strength training with the opposite (non-immobilised) arm, and some will wear special prism glasses during training that create the illusion that the immobilised arm is moving. We aim to test whether training the opposite arm, with or without visual feedback, can help reduce strength loss and maintain normal brain function. We expect that these approaches will help preserve muscle strength by maintaining communication between the brain and muscles.

This study addresses the lack of a uniform triage framework for glaucoma suspects, which currently varies depending on individual clinician judgement and referral quality. We will trial an RGEC inclusive of a clinical–genetic risk calculator to provide evidence-based, data-driven triage. This approach makes best use of current scientific advances in polygenic risk, translating them into practical tools for glaucoma care. There is an established global precedent in rapid and virtual assessment workflows, but these have not yet been implemented locally, creating an opportunity for RGEC to lead innovation in service delivery in South Australia. RGEC has the potential to improve patient access, reduce unnecessary hospital visits for low-risk individuals, prioritise timely care for high-risk patients, and increase efficiency in overburdened outpatient clinics. In doing so, the study contributes both to the scientific evidence base and to immediate improvements in clinical practice.

Despite improvements in neonatal intensive care for preterm infants, the burden of brain bleeds, termed Germinal Matrix-Intraventricular Haemorrhage, remains unchanged. Complications of GMH-IVH, including post-haemorrhagic ventricular dilatation (PHVD), are associated with significant long-term morbidity, including cerebral palsy and cognitive impairment. There are currently no readily available treatment options to treat GMH-IVH, prevent progression to PHVD and lessen neurodisability. Fresh maternal breastmilk, a rich source of reparative proteins, immune cells and stem cells, represents a promising treatment pathway. We propose that treating babies with GMH-IVH with a few intranasal drops of fresh mothers' own milk twice a day for 28 days will reduce PHVD. In this study babies will be randomly allocated to receive intranasal mothers' own milk or to standard care. All other aspects of the baby's care, including head ultrasounds and longer term developmental follow up, will be in accordance with routine care.

710GO-HV-01 is a first-in-human, double-blind, placebo-controlled study evaluating the safety and efficacy of EMBC-710GO as a single dose or multiple ascending doses in healthy adults who are overweight or have obesity. You may be eligible for this study if you are aged between 18 and 55, are male or female, have a BMI between 25-40kg/m2 and do not have clinically significant (CS) medical history. The aim of this study is to determine a safe and tolerable dose of 710GO, and to assess how the study drug interacts with the body. Part A (SAD) will evaluate different doses of 710GO to determine the maximum safe and well-tolerated dose. Part B (MAD) will investigate two dose levels from Part A in greater detail.

710GO-HV-01 Part C is a first-in-human, open-label, crossover study evaluating the safety, efficacy and pharmacokinetics of EMBC-710GO as a single dose when taken with food in healthy adults. You may be eligible for this study if you are aged between 18 and 55, are male or female, have a BMI between 18-30kg/m2, and do not have clinically significant (CS) medical history. The aim of this study is to determine a safe and tolerable dose of 710GO, and to assess how the study drug interacts with the body when unfed, or when taken with food. Part C will evaluate the effect of food intake on the study drug's safety, tolerability and interaction with the body.

[ Why Are We Doing This Research? ] The purpose of this study is to test a bilingual, non-clinical patient navigation program designed to help Chinese- and Vietnamese-speaking cancer survivors overcome language, cultural, and health-system barriers as they transition from hospital treatment back to their local GP and community care. [ Who Is It For? ] You may be eligible for this study if you are aged 18 or older, speak Mandarin, Cantonese, or Vietnamese at home, and have completed active cancer treatment within the last two years. [ Study Details ] Participants in this study will be randomly allocated to one of two groups. Participants in one group will receive "usual care," which includes their standard follow-up appointments and standard survivorship information .The other group will participate in the PEARL program for 12 months. This involves: 1) meetings with a trained bilingual Patient Navigator to identify barriers and create a personalized care plan ; 2) support from a "Peer Facilitator" - a cancer survivor from your same cultural background who provides practical assistance and mentorship in your language ; and 3) assistance connecting with your GP to ensure you have a long-term plan for your health and wellbeing . As part of the study, all participants will answer a series of questionnaires at the start, at 6 months, and at 12 months . The findings will inform sustainable, culturally responsive models of cancer survivor-ship care in Australian primary care.